Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/138214
Title: CD137L- DENDRITIC CELLS HAVE A NOVEL INFLAMMATORY PHENOTYPE AND INDUCE A POTENT TC1 RESPONSE AGAINST EPSTEIN-BARR VIRUS
Authors: BHUSHAN DHARMADHIKARI
Keywords: Dendritic cells, CD137 ligand, Immunotherapy, Cancer
Issue Date: 28-Apr-2017
Citation: BHUSHAN DHARMADHIKARI (2017-04-28). CD137L- DENDRITIC CELLS HAVE A NOVEL INFLAMMATORY PHENOTYPE AND INDUCE A POTENT TC1 RESPONSE AGAINST EPSTEIN-BARR VIRUS. ScholarBank@NUS Repository.
Abstract: Most clinical studies with dendritic cells (DCs) as anti-cancer vaccines have relied on GM-CSF + IL-4 derived cDCs. Although proven to be safe, the overall clinical benefits are low. These disappointing results are largely due the inability of cDCs to mount sufficiently strong T cell responses. In this study, we show that CD137L-DCs, generated via CD137L signaling, have a novel inflammatory phenotype and are closely related to in-vivo DCs. CD137L-DCs induce more potent CD8+ T cell response against cancer-associated Epstein-Barr virus and enhance the physiological of fitness of T cells. We thus report, CD137L-DCs as the next generation DCs for DC based immunotherapy. A phase I trial for treatment of Nasopharyngeal carcinoma (NCT03282617) is currently underway.
URI: http://scholarbank.nus.edu.sg/handle/10635/138214
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Dharmadhikari B.pdf2.17 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

54
checked on May 22, 2019

Download(s)

141
checked on May 22, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.